News & Resources

MEDIA COVERAGE
Press Releases
Articles
PRESENTATIONS
Events
View All
Press Release
Jun 20, 2024 |
ProJenX Announces Receipt of $1M Hoffman ALS Clinical Trial Award from the ALS Association
Read More
Press Release
Mar 28, 2024 |
ProJenX Announces Removal of Partial Clinical Hold for Prosetin Program by FDA
Read More
Press Release
Feb 14, 2024 |
ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS
Read More
Press Release
Nov 29, 2023 |
ProJenX Receives Health Canada Clinical Trial Application Authorization for First Study of Prosetin in People Living with ALS
Read More
Press Release
Nov 2, 2023 |
ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors
Read More
Press Release
Mar 30, 2023 |
ProJenX Announces Formation of Scientific Advisory Board
Read More
Events
Nov 16, 2022 |
Join ProJenX at the 2022 International Symposium on ALS/MND
Read More
Presentations
Nov 16, 2022 |
Safety and pharmacokinetics of prosetin, a novel, brain penetrant MAP4K inhibitor in development for the treatment of ALS
Read More
Media Coverage
Nov 16, 2022 | GEN: Genetic Engineering and Biotechnology News
Stress Test: ProJenX’s Oral Drug Shows Early Promise vs. ALS
Read More
Media Coverage
Nov 2, 2022 | BioCentury
ProJenX: Protecting Neurons to Treat ALS
Read More
Media Coverage
Sep 6, 2022 | BioSpace
ALS Thought Leaders Weigh in Ahead of Second Amylyx Adcomm
Read More
Press Release
May 18, 2022 | ProJenX
ProJenX Names Life Sciences Industry Veteran Stan E. Abel as CEO
Read More

Contact Us to Learn More About Our Fight Against ALS

Contact Us